Board Elects Marvyn Robar as First Independent, Non-Executive Chairman
HALIFAX, May 6, 2014 /CNW/ - MedMira Inc. (TSXV: MIR) announced today that its Board of Directors appointed Marvyn Robar and
Colin MacGillivray as Directors to serve until the next annual
shareholder meeting. Dr. Shou-Ching Tang retired from the Board of
Directors after 12 years of service. The Board thanks Dr. Tang for his
services and the guidance he provided to MedMira during his tenure as a
member of the Board. These changes were effective May 2, 2014.
The Board elected Mr. Robar as the Company's first non-executive
Chairman. Hermes Chan, CEO of MedMira, who served as interim Chairman,
will remain as the member of the Board. The appointment of Mr. Robar,
supports the Board's commitment to the advancement of MedMira's
corporate governance practices and policies and enables the
implementation of industry best practices within the Company.
"The diverse industry experience and backgrounds of both our new
Chairman and new director complements the expertise of our other Board
members. Being able to engage such respected independent directors
further aligns us with industry best practices in corporate governance
and positions us well to build upon our successes," said Hermes Chan,
Mr. Robar brings extensive experience to the role of Chairman of Board
with over 35 years in both the private and public sectors. Prior to his
retirement from the Government of Nova Scotia 2013, Mr. Robar served as
the Vice President, Investment, Department of Economic and Rural
Development and Tourism, in charge of the $700 million economic
development fund and as President of the Nova Scotia Strategic
Opportunities Fund Inc., a $250 million investment fund. In this role,
Mr. Robar had the opportunity to work with many of Nova Scotia's
largest companies as well as a range of small and medium sized
enterprises. He routinely provided advice and recommendations to the
Executive Council of the Province of Nova Scotia, ministers, and deputy
ministers across a broad range of departments on files and portfolios.
After completing a BSc in chemistry/math and working as a chemist at
the Nova Scotia Research Foundation, Mr. Robar returned to Dalhousie
University, obtained an MBA and subsequently, went on to join
PricewaterhouseCoopers and earn his Chartered Accountancy designation.
"I look forward to working closely with other experienced Board members,
Hermes, and his management team as we continue the Company's focus on
innovation and revenue generation," said Marvyn Robar, Chairman of
MedMira. "MedMira is a company that is reinventing the rapid
diagnostics sector with its distinct technology and the Board is fully
committed to guiding this Company forward and delivering on its promise
of increasing shareholder value through strategic growth."
The Board also appointed Colin MacGillivray as a Director. Dr.
MacGillivray has over 20 years of experience including finance and
operating experience in life sciences across multiple geographies with
Elan Pharmaceuticals Inc., Lundbeck Inc. (the US subsidiary of H.
Lundbeck A/S, Denmark) and Biolytical Laboratories, along with broader
experience from a range of other industries. Dr. MacGillivray is a
Member of the Institute of Chartered Accountants in England & Wales
having qualified with PricewaterhouseCoopers. He received his Ph.D.
from the Department of Animal & Plant Sciences, University of Sheffield
following undergraduate studies at the University of Edinburgh.
MedMira is a leading developer and manufacturer of vertical flow rapid
diagnostics. The Company's tests provide hospitals, labs, clinics and
individuals with instant diagnosis for diseases such as HIV and
hepatitis C in just three easy steps. The Company's tests are sold
under the Reveal®, Multiplo™ and Miriad™ brands in global markets. Based on its patented
Rapid Vertical Flow Technology™, MedMira's rapid HIV test is the only
one in the world to achieve regulatory approvals in Canada, the United
States, China and the European Union. MedMira's corporate offices and
manufacturing facilities are located in Halifax, Nova Scotia, Canada.
For more information visit medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
approval and launch of new products, future growth, and new business
opportunities. Actual events could materially differ from those
projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MedMira Inc.
For further information:
Andrea Young, Corporate Communications